Login to Your Account



Merrion Stock Surges on $58M Novo Nordisk Deal

By Cormac Sheridan


Wednesday, November 26, 2008
DUBLIN, Ireland – Shares in Merrion Pharmaceuticals plc (DUBLIN:MERR) surged 42 percent Monday on news that the company had secured a licensing deal with Novo Nordisk for the oral delivery of the latter company's proprietary insulin analogues. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription